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Abstract
Hepatitis C virus (HCV) induced liver disease is the leading indication for liver transplantation (LTx). Reinfection and
accelerated development of fibrosis is a universal phenomenon following LTx. The molecular events that lead to fibrosis
following HCV infection still remains poorly defined. In this study, we determined microRNA (miRNA) and mRNA expression
profiles in livers from chronic HCV patients and normals using microarrays. Using Genego software and pathway finder we
performed an interactive analysis to identify target genes that are modulated by miRNAs. 22 miRNAs were up regulated (.2
fold) and 35 miRNAs were down regulated (.2fold) compared to controls. Liver from HCV patients demonstrated increased
expression of 306 genes (.3 fold) and reduced expression of 133 genes (.3 fold). Combinatorial analysis of the networks
modulated by the miRNAs identified regulation of the phospholipase C pathway (miR200c, miR20b, and miR31through
cellular proto-oncogene tyrosine-protein kinase Src (cSrc)), response to growth factors and hormones (miR141, miR107 and
miR200c through peroxisome proliferator-activated receptor alpha and extracellular-signal-regulated kinases, and
regulation of cellular proliferation (miR20b, miR10b, and miR141 through cyclin-dependent kinase inhibitor 1 or CDK-
interacting protein 1 p21). Real time PCR (RT-PCR) validation of the miRNA in HCV infected livers demonstrated a 3.3 60.9
fold increase in miR200c. In vitro transfection of fibroblasts with miR200c resulted in a 2.2 fold reduction in expression of
tyrosine-protein phosphatase non-receptor type 13 or FAS associated phosphatase 1 (FAP-1) and 2.3 fold increase in
expression of cSrc. miR200c transfection resulted in significant increases in expression of collagen and fibroblast growth
factor (2.8 and 3.4 fold, p,0.05). Therefore, we propose that HCV induced increased expression of miR200c can down
modulate the expression of FAP1, a critical regulator of Src and MAP kinase pathway that play an important role in the
production of fibrogenic growth factors and development of fibrosis.
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Introduction
Hepatic fibrosis is a complex biological process that is
progressive in nature leading to the development of cirrhosis and
later to the development of hepatocellular carcinoma. Hepatitis C
infection is attributed to be involved in more than 40% of the
chronic liver disease and remains the major reason for liver
transplantation (LTx) in US and Europe [1]. Approximately 3% of
the global population or 170 million people are infected with
Hepatitis C virus (HCV) [2]. In the HCV infected transplant
recipients reinfection of the transplanted liver is a universal
phenomenon and the resulting fibrosis follow an accelerated
progression [3].
Chronic liver injury results in inflammation, apoptotic cell death
of the hepatocytes and initiation of a wound healing response that
results in the development of fibrous deposition leading to
development of fibrosis [4]. Myofibroblasts developed from the
hepatic stellate cells have been shown to play a major role in the
development of liver fibrosis [5]. Development of fibrosis following
chronic HCV infection plays a pivotal role in loss of liver function
resulting in end stage liver diseases. Increased expression of pro-
fibrogenic growth factors including transforming growth factor-b
(TGF-b), hyaluron and extra cellular matrix proteins has been
correlated with the degree of fibrosis in the liver [6]. B cells
infiltrating the liver and Th17 cells have been shown to be
important sources of cytokine IL-6, which is involved in the
differentiation of hepatic stellate cells into myofibroblasts, induc-
tion of fibroblast proliferation, and the increased synthesis of
extracellular matrix collagens and metalloproteinase inhibitors [7].
Chronic inflammation leads to the activation of hepatic stellate
cells to produce extracellular matrix proteins and growth factors
that are involved in the increased proliferation of the fibroblasts as
well as deposition of the fibrous scar leading to loss of liver
function [8]. Increased levels of TGF-b [9], platelet derived
growth factor (PDGF) [10], fibroblast growth factor (FGF),
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hepatocyte growth factor [11], and vascular endothelial growth
factor (VEGF) [12] have been reported in the chronic HCV
individuals and are thought to play a crucial role in the
fibroproliferative cascade leading to development of fibrosis. Upon
binding of the fibrogenic growth factors (TGF-b and FGF) to their
cognate receptor on the target cells results in the activation of cSrc,
Mitogen-activated protein kinase (MAPK) and Extracellular
Signal-regulated Kinase (ERK) leading to increased production
of growth factors and extracellular matrix proteins resulting in
development of fibrosis [13,14]. However the mechanisms by
which HCV infection modulate the process of fibrosis still remains
poorly defined.
Non coding RNAs have been shown to participate in a variety
of cell regulatory events [15]. microRNAs (miRNAs) are a family
of 21–25 nucleotide RNAs that were initially discovered as small
temporal RNAs regulating developmental events in C. elegans
[16]. There are hundreds of miRNAs that have been described in
various species and they have been implicated in negatively
regulating gene expression at the post transcriptional level [17].
They have diverse expression patterns and regulate many events in
development and cell physiology [18]. The mechanisms by which
miRNA regulate gene expression are still poorly defined, but the
finding of miRNAs feeding into RNA interference pathway has
been important in understanding their biological functions.
miRNAs have been shown to play an important role in immune
evasion, cell cycle regulation and in cancer progression [19]. HCV
infection has been shown to modulate miRNA levels in
hepatocytes that are involved in HCV entry, propagation and
immune evasion [20].
In this study we demonstrate that HCV infection results in the
modulation of miRNA and these mRNA changes in the liver can
promote growth factor signaling, cell proliferation and survival.
We also demonstrate that increased levels of miR200c in the HCV
infected livers results in the inhibition of FAS associated
phosphatase 1 (FAP-1), a protein tyrosine phosphatase. FAP-1, a
multimodule tyrosine phosphatase regulates the function of Src
kinase by dephosphorylation that plays an essential role in
activation of the down-stream signaling cascades of growth factors.
We propose that these events will result in increased production of
pro-fibrogenic growth factors and products of extracellular matrix




All of the human studies were approved by the human research
protection committee at Washington University (protocol
201104075) and patients were enrolled after written informed
consent was obtained.
Patient population
Patients with documented HCV infection confirmed by HCV
RNA quantitative polymerase chain reaction (PCR) assays with a
lower detection limit of 50 IU/mL (Cobas Amplicor, Roche
Diagnostics) were enrolled in this study. Patients with Hepatitis B
virus (HBV) or HIV co-infection were excluded from the study.
Liver biopsies obtained from patients infected with HCV during
routine follow-up were used in this study. Liver biopsies were
scored for fibrosis with the Scheuer staging system. Liver biopsies
procured from donor livers prior to transplantation were used as
normal controls. Liver biopsies obtained from 10 HCV patients
with absent/minimal evidence of allograft fibrosis (S0–S2) and
varying grades of allograft inflammation (G0–G4) and 10 liver
biopsies obtained from patients with non-alcoholic steatohepatitis
were also procured. No donor organs were obtained from
executed prisoners or other institutionalized persons. The
demographic profile of the patient population is presented in
Table 1. Serum samples were also collected at the time of liver
biopsy.
Gene array and miRNA array analysis
Liver biopsy that were snap frozen obtained from HCV or
control normal liver, were used to isolate RNA using Trizol
reagent (Invitrogen, Carlsbad, CA) as per manufacturer’s protocol.
Resulting RNA was quantified by A260 and A280 readings using a
Nanodrop spectrophotometer (Nanodrop Technologies, Wilming-
ton DE) and qualitatively assessed using a BioAnalyzer 2100 and
RNANanoChip assay (Agilent Technologies, Palo Alto, CA). All
nucleic acid extraction procedures were performed by the Siteman
Cancer Center Tissue Procurement Core (Washington Universi-
ty). miRNA microarray data and mRNA microarray data for
samples was generated with Illumina Bead arrays in the Siteman
Cancer Center Molecular and Genomic Analysis Core (Washing-
ton University) starting with 1 mg of quality controlled total cellular
RNA as per standard protocols. Both miRNA and mRNA data
were analyzed in Partek Genomic Suite (Version 6.6) following
background subtraction and quantile normalization in Illumina
Genome Studio platform. Control probes and probe sets that were
called ‘‘Absent’’ across all samples were removed prior to any
analysis. Analysis of Variance (ANOVA) algorithm as implement-
ed in Partek was used to compare the miRNA and mRNA
expression pattern in liver biopsies between the HCV patients and
normal donors at statistical significance p, 0.05. The differentially
expressed miRNA in the mRNA was used to identify the gene
ontological processes as well as the signaling networks targeted
using the Genego software.
Validation of the array data using quantitative RT-PCR
Results from the miRNA and the mRNA arrays were validated
using quantitative RT-PCR. Liver biopsies from 10 patients with
HCV with grade III/IV fibrosis, 10 patients with HCV infection
but no fibrosis and 10 patients with nonalcoholic steatohepatitis
were used to validate the array data.





Age (yrs) 49.169.8 52.36 7.4 50.165.7










Fibrosis stage(S) S2–S4 S0 3–4









HCV load (log IU/ml) 13.362.6 12.465.6 N/A
ALT [Mean(range)] IU/ml 111(45-326) 126 (67-367) 72 (36-315)
AST [Mean(range)] IU/ml 103(26-271) 98 (54-278) 67 (33-214)
doi:10.1371/journal.pone.0070744.t001
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Isolation of primary human liver fibroblasts
Primary human liver fibroblasts were isolated from donor liver
(n = 2) as described earlier [21] with certain modifications. Briefly,
the liver tissue (0.565 mm) was washed twice in RPMI, minced
with surgical blades under aseptic conditions and digested
overnight with collagenase (1 mg/mL), filtered to remove undi-
gested tissue remnants and layered on collagen 1-coated plates and
cultured for 7 days at 37uC in 5% CO2 and harvested by
trypsinization for further studies.
Functional studies
In order to determine the function of miR-200c, we transfected
16106 human liver fibroblasts (ATCC, Manassas, VA) or isolated
primary human liver fibroblasts with 200 nM of Pre-miRTM
miRNA Precursor -miR200c, -miR141 or scrambled miRNA
(Invitrogen, Carlsbad, CA) using LipofectamineH RNAiMAX
(Invitrogen, Carlsbad, CA). Transfected cells were stimulated with
50 ng/ml of recombinant human TGF-b (R&D systems) for 24
hrs. Levels of miR-200c, FAP-1 and FGF were analyzed by
quantitative RT-PCR using Taqman pre-developed assays (Ap-
plied Biosystems, Foster City, CA). Liver fibroblasts were
cotransfected with 50 nM of mirVanaH miRNA inhibitor and
200 nM of pre-miR miRNA to discern the role of individual
miRNA in modulation of the target gene. Cells were treated with
Src inhibitor-1 (10 mM, Sigma-Aldrich, St Louis, MO) or controls
during stimulation with TGF-b to discern the role of Src signaling.
Protein levels of activated cSrc and FAP-1 were analyzed by
western blot analysis.
RT-PCR analysis
Total RNA, including miRNAs was extracted using the Trizol
reagent (Invitrogen, Carlsbad, CA). miRNA expression was
measured by quantitative PCR using Biorad iCycler RT-PCR
machine. miRNA TaqMan primers and probes were purchased
from Applied Biosystems (Foster City, CA). The small RNA U6b
was used as an endogenous control and relative miRNA quantity
was calculated by the DDCt method. Gene expression was
measured by quantitative PCR using Biorad iCycler RT-PCR
machine. Gene expression assay TaqMan primers and probes,
TaqManH One-Step RT-PCR Master Mix were purchased from
Applied Biosystems (Foster City, CA). For gene expression
studies, the human actin B (ACTB) was used as an endogenous
control and the relative gene expression levels were calculated by
the DDCt method and the fold changes in the control and
experimental groups were compared by student t test.
Protein expression
Expression levels of the genes at the protein level were
determined by Western blotting as previously described. The
primary antibodies used in this study are cSrc (Cell Signaling),
FAP1 (Cell Signaling), and b-Actin (Santa Cruz Biotechnology).
The western blots were developed with SuperSignal West Pico
Chemiluminescent kit (Pierce Biotechnology, Rockford, IL).
Densitometric analysis of the bands was performed using
QuantityOne software (Biorad, CA) and the expression values in
the experimental and control (untransfected) groups were com-
pared by student t test.
TGF-b ELISA
Circulating levels of TGF-b in the serum of chronic HCV
patients and normal subjects were analyzed using Human TGF-b
1 Quantikine ELISA Kit (R&D systems, Minneapolis, MN) as
per manufacturers’ instruction. Briefly, to activate the latent
TGF-b to immunoreactive TGF-b, 40 mL of serum sample was
added to 20 mL of1N HCl and incubated for 10 minutes at room
temperature and neutralized by adding 20 mL of 1.2N NaOH/
0.5M HEPES. The samples were further diluted 20 fold with
calibrator diluent RD5-53. 50 mL of assay diluent and 50 mL of
diluted serum sample or standards were added to each well and
incubated for 2 hours at room temperature. The wells were
washed (4X) and incubated with 100 mL of TGF-b conjugate
and incubated for 2 hours at room temperature. The plates were
developed with 100 mL of substrate solution for 30 minutes and
stopped with 100 mL of stop solution and the optical density was
measured at 450 nm and corrected by measurements at 540 nm.
A standard curve was generated using 4 parameter logistic curve
fit and used to calculate the concentrations in the serum sample.
Results
HCV infection results in modulation of miRNA profile
In order to determine the effect of chronic HCV infection in
the expression of miRNAs we analyzed the miRNA expression
profile in liver biopsies of chronic HCV patients and compared
them to normal healthy livers procured for transplantation. Total
RNA was isolated from the liver biopsies and miRNA expression
analysis was done using the Illumina V2 human array that
contains (1146) probe sets. Anova analysis of the miRNA levels
demonstrated significant differences in the miRNA profiles
between the two groups (p,0.05). Changes in expression level
of 2-fold or more in the HCV samples compared with the
normal controls were considered to be significant. The data
discussed in this publication have been deposited in NCBI’s
Gene Expression Omnibus (Edgar et al., 2002) and are accessible
through GEO Series accession number GSE38226 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE38226). In 6 of
the 8 samples that demonstrated a significant difference we
identified 22 miRNAs that are up regulated (.2 fold) and 35
miRNAs that are down regulated (.2 fold) in the liver of HCV
patients compared to controls (Table 2). A significant increase in
the expression of miR144 (11.77 fold, p= 0.022), miR31 (7.87
fold, p = 0.002), miR141 (3.40 fold, p= 0.009) and miR200c
(2.95 fold, p = 0.02) were observed in the chronic HCV infected
liver compared to the controls. Similarly the levels of miR802
(4.97 fold, p = 0.001), miR556-3p (4.5 fold, p = 0.0042) and
miR615-5p (3.67 fold, p,0.001) were significantly down
regulated in the livers from chronic HCV patients compared to
the controls. The miRNAs that are modulated in chronic HCV
liver is presented in Table 2. Gene ontological grouping of the
differentially expressed miRNAs identified phospholipase C
activating G protein coupled receptor signaling pathway
(miR220c, miR20b and miR31), response to endogenous
stimulus (miR141, miR107, miR200c), regulation of cellular
processes (miR20b, miR10b and miR141), response to wound
healing (miR34c) and leucocyte migration (miR483) as the major
gene ontological processes that could be modulated by the
differentially expressed miRNAs in the chronic HCV infected
liver. These results are consistent with the possibility that the
differentially expressed miRNAs in the HCV infected liver may
play a significant role in the development of fibrosis.
Identification of the target genes that are modulated by
chronic HCV infection
To identify the target genes that are modulated by miRNAs,
we performed a whole genome microarray on the liver biopsies
from 8 chronic HCV patients and compared them to normal
livers. Total RNA was isolated from the liver biopsies and
HCV Induced microRNA Promote Fibrosis Development
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mRNA expression analysis was done using the Illumina Human
HT-12 v3 Expression BeadChips array that contains (48000)
probe sets. Gene expression levels in the samples were
normalized based on the 16s ribosomal RNAs and housekeeping
gene expression. Using PARTEK analysis software we analyzed
the expression levels of the genes. Changes in gene expression
level of 2-fold or more in the HCV samples compared with the
normal controls were considered to be significant. Chronic HCV
patients had greater than two fold increases in the expression of
785 genes and greater than 2 fold reduction in the expression of
533 genes. Functional grouping of the modulated genes (Table 3)
identified components of the cell cycle regulation/apoptosis
pathways (NFkB, Bcl2 and cIAP, cSRC, BRCA1 and TCF4),
immune function (HLA-A, IRF-1, MxA, MGAT2 and ASCL1),
and cellular response to growth factor stimulus (ILK, cSRC,
STAT3) as the major gene ontological processes modulated by
HCV infection. These results support that the differentially
expressed genes in the HCV livers can influence many of the
major biological processes.
miRNA mediated changes in gene expression during HCV
infection affects cellular pathways implicated in chronic
HCV infection
In order to identify the genes that are targeted by the modulated
miRNAs in the chronic HCV infected liver we combined the
differentially expressed miRNAs and the differentially expressed
mRNAs in the Partek miRNA analysis using the Targetscan 5.0
database. Potential interactions, as many as 289, were defined
between the differentially expressed miRNAs and mRNAs
identified in the HCV infected liver (Table 4). In order to
delineate the biological significance we used the combined miRNA
and mRNA pairs to build networks using Genego software. The
biological processes that are modulated by chronic HCV infection
are presented in figure 1. Among all the biological processes,
multiple hits were observed in the ‘‘cellular response to endoge-
nous stimulus through growth factors’’ pathways suggesting that
HCV infection results in differential expression of miRNAs that
modulate cellular response to endogenous stimulus including
growth factors which can promote development of fibrosis.
Analysis of the networks modulated by the miRNAs (figure 2a,
b, c) identified regulation of the phospholipase C pathway
Table 2. miRNA expression profile in chronic HCV.
ID p-value Fold Change ID2 p-value Fold Change
hsa-miR-144 0.0228226 11.7742 hsa-miR-431 0.0357257 22.00977
hsa-miR-31* 0.002818 7.86888 hsa-miR-651 1.96E-06 -2.0156
hsa-miR-486-3p 0.0186293 7.46136 hsa-miR-1275 0.00111948 -2.07652
hsa-miR-144:9.1 0.030492 6.98866 hsa-miR-616* 0.00798456 -2.10282
hsa-miR-31 0.00681662 5.08077 hsa-miR-196a* 0.0335879 -2.11588
HS_176 0.018694 4.73535 hsa-miR-193b* 0.00722542 -2.13796
hsa-miR-708 0.00867611 3.83595 hsa-miR-24-1* 5.42E-06 -2.16046
hsa-miR-10b 0.0125468 3.69579 solexa-15-44487 0.0468131 -2.17189
hsa-miR-141 0.00995113 3.40592 hsa-miR-128a:9.1 0.00246633 -2.24699
hsa-miR-182 0.0116925 3.38087 hsa-miR-548j 0.00279194 -2.25898
hsa-miR-34c-3p 0.0320449 2.97359 hsa-miR-483-5p 0.00560094 -2.28867
hsa-miR-200c 0.0245857 2.94861 hsa-miR-128b:9.1 0.0107908 -2.31064
hsa-miR-486-5p 0.00281192 2.79836 hsa-miR-548b-3p 0.0134523 -2.31549
HS_97 0.0265193 2.66399 hsa-miR-449a 0.007856 -2.38192
hsa-miR-138 0.0375211 2.62481 hsa-miR-148a* 8.88E-05 -2.46658
HS_263.1 0.00630278 2.61126 hsa-miR-23b* 0.000776048 -2.4976
hsa-miR-218 0.0485095 2.59988 hsa-miR-194* 7.52E-05 -2.51704
hsa-miR-34b* 0.00826268 2.31809 hsa-miR-107 0.0151007 -2.53139
hsa-miR-125b-1* 0.00738561 2.22584 hsa-miR-548o 0.0154111 -2.5446
hsa-miR-20b 0.0282687 2.21857 hsa-miR-92a-1* 0.005961 -2.58038
HS_203 0.00936761 2.15614 hsa-miR-616 0.000142243 -2.73623
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(miR200c, miR20b, and miR31 through cSrc) (figure 2a), response
to endogenous stimulus of growth factors and hormones (miR141,
miR107 and miR200c through Peroxisome proliferator-activated
receptors-a (PPAR-a) and ERK (figure 2b)), and regulation of
cellular proliferation (miR20b, miR10b, and miR141 through
p21) (figure 2c). The list of putative networks that are modulated
by the miRNAs in the chronic HCV infected liver is presented in
Table 5.
Table 3. Transcriptional modulation of biological networks in chronic HCV infection.
Key network objects GO Processes Seed nodes p-Value zScore gScore
NF-kB, Bcl-2, c-IAP1, c-IAP2,
Leptin receptor
regulation of programmed cell death (80.0%),
positive regulation of cellular process (98.0%)
11 8.43e-09 9.65 172.15
c-Src, Brca1, DAB2, TCF7L2
(TCF4), NF-kB2 (p100)
regulation of cell proliferation (66.0%), Wnt receptor
signaling pathway (40.0%),
10 5.93e-08 8.99 57.74
ILK, c-Src, STAT3, Neuropilin-1, SHIP transmembrane receptor protein tyrosine kinase
signaling pathway (60.7%), cellular response to growth factor
stimulus (51.8%),
11 1.86e-08 9.24 21.74
Alpha1-globin, Phox1 (PRRX1),
PGHD, miR-107, SLIT2
regulation of response to stimulus (71.1%), regulation of
cell death (53.3%), regulation of signaling (60.0%)
19 7.54e-20 18.20 19.45
STK39, HAI-2, ITM2C, PDCD4, P4HA1 multicellular organismal response to stress (16.0%) 16 7.22e-16 15.52 19.27
HLA-A, IRF1, MxA, MGAT2, ACSL1 antigen processing and presentation of endogenous
peptide antigen (24.0%), positive regulation of T cell
mediated cytotoxicity (24.0%)
13 1.02e-11 12.28 18.53
WARS, ICAM3, STAT1, alpha-
D/beta-2 integrin, ITGAX
response to other organism (43.6%), immune response
(43.6%), defense response to virus (20.5%)
16 3.29e-16 15.90 17.15
SLC34A1, COL6A2, F-spondin,
IMPA2, SMOC2
Gamma-aminobutyric acid signaling pathway (27.1%) 17 4.09e-17 16.36 16.36
NKCC1, ACACB, BETA-IG-H3,
PCSK9, HCD2
Second-messenger-mediated signaling (21.7%) 16 1.52e-15 15.17 15.17
Ephrin-B receptor 6,
MIR (Idol), PTPR-epsilon
Ephrin enzyme linked receptor protein signaling pathway
(37.5%)
12 1.79e-10 11.26 13.76
doi:10.1371/journal.pone.0070744.t003
Figure 1. Pathways modulated in chronic HCV. RNA from liver biopsies from 8 HCV patients and normal donor livers were isolated using Trizol
reagent and miRNA expression profile in the samples were analyzed using Illumina Bead array. The differentially expressed miRNA identified using
Partek analysis were grouped based on the biological pathways that could be modulated.
doi:10.1371/journal.pone.0070744.g001
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Increased TGF-b production in chronic HCV
It is well accepted that TGF-b plays a crucial role in the
development and progression of fibrosis [22]. Therefore, we
measured the levels of TGF-b in the sera of 20 chronic HCV and
compared them to normal subjects using a TGF-b ELISA kit. As
shown in figure 3, ELISA results demonstrated significant
increases in the levels of TGF-b in the sera from chronic HCV
patients when compared to healthy controls (450 vs. 64 ug/ml,
p,0.05).
Transfection of human liver fibroblasts with miR200c
decreases expression of FAP-1
Since analysis of the miRNA and mRNA expression profiles
identified that there was a significant modulation of miR200c
along with its target (FAP-1) and downstream signaling interme-
diates (cSRC, FGF, and extracellular matrix components) that can
promote the development of fibrosis, the miR200c pathway was
selected for further analysis. The miRNA analysis showed that
miRNA-200c is up regulated (2.9 fold) in HCV patients compared
to normal (Table 2). Computational target prediction of miR200C
using Targetscan (Targetscan.org) identified FAP1 (Tyrosine-
protein phosphatase non-receptor type 13, PTPN13) to be a
putative target for translational silencing. In order to investigate
the role of miR200c in the development of fibrosis, we transfected
normal human liver fibroblasts (CRL11005, ATCC or 2
fibroblasts isolated from donor livers) with pre-miR200c, control
miRNA or pre-miR141 (shares the 59 seed sequence of miR200c)
and expression of both miRNA-200C and FAP1 were determined
by quantitative RT-PCR following stimulation with TGF-b. The
miR200c results were normalized to small RNA U6b levels and
FAP-1 levels were normalized with GAPDH expression. A 2.7 fold
increase in the levels of miR200c was observed in the fibroblasts
when transfected with miR200c, however, the levels of miR200c
were unaffected when transfected with miR141 or scrambled
miRNA (figure 4a). Transfection with miR200c resulted in a 2.46
0.3 fold (figure 4b) reduction in the levels of FAP-1 when
compared to fibroblasts transfected with miR141 or scrambled
Table 4. mRNAs targeted by the modulated miRNA in chronic HCV.
ID SYMBOL
hsa-miR-144 ZNF532, MYH10, COL5A2, DUSP5, ALDH1A3, DUSP1, CUGBP2, FLJ20160, CEP135, RUNX1, PDCD4, PRRX1, ARHGEF3, FOSB, PAPPA, TGIF1,
PCDH18
hsa-miR-486-3p CLIP3, STEAP3, MLLT6, NAMPT
hsa-miR-31 COL5A1, PC, STX3, KLF13
hsa-miR-708 DKK3, HNT, DKK3
hsa-miR-10b TPM4, MAPRE1, CUGBP2, KCNA6, TPM4
hsa-miR-141 MOBKL2B, MYH10, DOCK4, TCF4, GPHN, SPG3A, SCD5, RUNX1, PDCD4, GLS, PAPPA, FRMD6
hsa-miR-182 ANXA11, COL5A1, LAMC1, PC, MOBKL2B, ZNF532, CMTM7, MAPRE1, F13A1,ANXA11, FZD5, LIPG, DOCK4, NAP1L1, CUGBP2, PLOD2,
HBEGF, DKFZP564O0823, INSIG1, DDEF1, CLPTM1L, KLF13, SAMD5, ARHGEF3, EVI1, PHLDB1,PAPPA, MYADM, ATOH8, BCL2, RAB34, THBS2,
NAMPT, PCDH18
hsa-miR-34c-3p CD34, GLS, PPP1R1A, SLITRK3, MTUS1
hsa-miR-200c PTPN13, SNAP25, LFNG, C5orf13, ABAT, LAMC1, C3orf23, ZNF532, LEPR, CDR2L, MAPRE1, NIN, DOCK4, DUSP1, CUGBP2, TCF4, DDIT4,
DDEF1, CREB5, KLF13, ABCC9, OSR1, ARHGEF3, KLF4, TIMP2, SGIP1, PHLDB1, KIAA0644, NIN, BCL2, MTUS1, COL4A3, LPAR1, HPS5, FRMD6
hsa-miR-486-5p EPHA3, CUGBP2, OLFM4
hsa-miR-138 SNAP25, SNCAIP, ADAMTS5, SCRN1, MAPRE1, TCF4, GPHN, VIM, HK1, SH3GL2, ARHGEF3, MLLT6, RASL12, PAPPA
hsa-miR-218 ABAT, PLEK, DUSP5, TCF4, ACSL1, INSIG1, BRCA1
hsa-miR-20b SAR1B, OSBPL5, PLXNA1, ADAMTS5, UGDH, PTPN3, ZNF532, ARHGEF10, MAPRE1, FAM129A, NIN, DOCK4, FURIN, IRF1, CUGBP2, TCF4,
NR4A3, FJX1, SCD5, CREB5, RUNX1, DPYSL2, PRRX1, EGR2, OSR1, SLITRK3, ARHGEF3, TIMP2, MLLT6, GLIS3, NR4A2, NIN, COL4A3, DAB2,
HPS5, FRMD6
hsa-miR-431 COL12A1
hsa-miR-651 BCL2, KDELR2, DHCR24, ZHX3
hsa-miR-548j MAB21L2, ZFPM2, ADARB1, CD44, STAT3, CSNK1E, CD44, SMOC2, MXRA7, FLRT2, RALGPS1, CAV1
hsa-miR-548b-3p DAB2, BCL11A, FGF9, NAMPT, PPP2R1B
hsa-miR-449a MYH9, ANK3, RALGDS, BCL2, EI24, NR4A2, SIDT1, SLC7A6, SGSM2, CREB5, PDE4B, CNTNAP1, COL12A1, PDE4B, VCL, JAG1, CACNB3, GAS1,
PID1, MMAB SLC12A2, SOX4, PODXL, RALGPS1, SEMA4B
hsa-miR-107 ST8SIA4, THY1, MYH9, ANK3, ZFPM2, BCL11A, RNF19A, SVEP1, CREB5, CNTNAP1, HIPK2, VCL, ZHX3, GPR124, SRGAP1
hsa-miR-548o C5orf29, MARCKS, ST3GAL6, PMEPA1, DAB2, MEF2C, ANTXR1, JAG1, FLRT2, MRPL22,
hsa-miR-616 NTN1, ANTXR1, MMAB
hsa-miR-592 ABCA1, BHLHB3, CYP1B1
hsa-miR-1258 YWHAZ, DDEF1, SGSM2
hsa-miR-556-5p CREB5, HIPK2, RCC2, LHFPL3
hsa-miR-615-5p BRCA1, CD3E, DBN1, TBC1D10C, OAS3, MPDU1
hsa-miR-556-3p COL4A1, B3GALNT1, DTX3L, TGFBI, IMPA2, MSRB3, NAMPT, CSNK1E, HIPK2, NCK2
hsa-miR-802 YWHAZ, RTN1, ZFPM2, CDH11, TSHZ3, HIPK2, LHFPL3, TADA1L
doi:10.1371/journal.pone.0070744.t004
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miRNA. Further cotransfection with mirVanaH miRNA inhibitor
for miR200c resulted in blocking the function of miR200c in the
miR200c transfected fibroblast leading to an increase in the
expression of FAP-1 similar to that observed in the untransfected
or scrambled miRNA transfected fibroblast (0.860.4 vs 2.360.2,
p,0.05).
miR200c overexpression promotes fibrosis by
modulating growth factor signaling through cSRC
activation
In silico combinatorial analysis of the miRNA and mRNA array
data demonstrated that miR200c targets src signaling by directly
targeting FAP1, a critical event in the development of fibrosis
(figure 2). Murielle Glondu-Lassis et al have shown that PTPN13
or FAP-1, a phosphatase can inhibit Src through direct
dephosphorylation in intact cells [23]. In order to determine the
biological role of miR200c in the development of fibrosis we
transfected primary human liver fibroblasts with pre-miR200c and
stimulated them with TGF-b for 24 hrs and analyzed the levels of
cSrc at the message level by quantitative RT-PCR and activated
cSrc and FGF at protein level by western blot analysis. A 2.6 fold
increase (p,0.05) in the levels of cSrc expression at the message
level was observed in the fibroblasts transfected with miR200c
(figure 5a). Blocking of the miR200c by cotransfection with
Figure 2. Biological networks modulated by the differentially expressed miRNA in chronic HCV. The biological networks modulated by
differentially expressed miRNA following HCV infection was analyzed using the Genego software. Genego analysis of the networks identified: a)
regulation of the phospholipase C pathway (miR200c, miR20b, and miR31 through cSrc); b) response to endogenous stimulus of growth factors and
hormones (miR141, miR107 and miR200c through PPAR-a and ERK); and c) regulation of cellular proliferation (miR20b, miR10b, and miR141 through
p21) as the major biological pathways that are impacted.
doi:10.1371/journal.pone.0070744.g002
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mirVanaH miRNA inhibitor for miR200c resulted in amelioration
of the increased expression of cSrc observed in the miR200c
transfected fibroblasts to the levels observed in the untransfected
or scrambled miRNA transfected controls (1.360.4 vs 2.860.4,
p,0.05). Western blot analysis of the levels of cSrc levels
demonstrated a 3.1 fold increase (p,0.05) in the fibroblasts
transfected with miR200c when compared to fibroblasts trans-
fected with scrambled miRNA (figure 5b). Similarly, western blot
analysis also demonstrated a 4.2 fold increase (p,0.05) in the
levels of FGF in the miR200c transfected fibroblasts when
compared to scrambled miRNA transfected fibroblasts
(figure 5b). These results demonstrate that miR200c targets the
cSrc regulator FAP1 leading to dysregulated signaling through the
growth factors leading to increased production of pro-fibrogenic
growth factors.
miR200c promotes fibrosis through dysregulation of cSrc
signaling cascade
In order to determine the signaling cascade through which
miR200c may promote fibrosis, we transfected human liver
Table 5. Gene Ontological process affected by miRNAs.
Key network objects GO Processes Total nodes Seed nodes p Value zScore gScore
miR 200c, microRNA 200c,
miR 20b, miR 31*, c Src
phospholipase C activating G protein coupled
receptor signaling pathway (21.3%), cell
communication (76.6%), signal
transduction (72.3%)
50 4 8.96e 08 19.56 19.56
miR 141, microRNA 107,
miR 200c, PPAR alpha, ERK1/2
response to endogenous stimulus (58.3%),
positive regulation of biological process (77.8%),
positive regulation of cellular process (75.0%)
50 3 8.75e 06 14.93 14.93
miR 20b, miR 10b,
microRNA 141, p21, Shc
developmental process (91.5%), anatomical
structure development (87.2%), positive
regulation of cellular process (80.9%), positive
regulation of biological process (83.0%)
50 3 9.90e 06 14.62 14.62
microRNA 20b, miR 182,
microRNA 31, CREB1, Bax
cellular response to chemical stimulus (51.1%),
cellular response to organic substance (44.4%),
response to inorganic substance (31.1%), response
to organic substance (53.3%)
50 3 9.90e 06 14.62 14.62
miR 34c 3p, Beta catenin,
CDK1 (p34), c Raf 1, GLUT4
positive regulation of cellular process (85.3%),
positive regulation of macromolecule metabolic
process (70.6%), positive regulation of biological
process (85.3%)
38 1 3.07e 02 5.49 5.49
miR 34c 5p, c Myb, Histone
H3, Collagen I, PLAU (UPA)
response to wounding (63.6%), wound healing
(50.0%), coagulation (45.5%), blood coagulation
(45.5%), hemostasis (45.5%)
50 1 3.71e 02 4.96 4.96
microRNA 483, FAK1,
G protein alpha i family,
NF I, eIF4E
leukocyte migration (36.7%), hemostasis
(44.9%), neuron projection development (46.9%)
50 1 4.02e 02 4.74 4.74
doi:10.1371/journal.pone.0070744.t005
Figure 3. Increased TGF-b in serum of HCV patients. We measured the levels of TGF-b in the sera of chronic HCV patients and compared them
to normal subjects using a TGF-b ELISA kit. The bars represent the mean 6 SD levels of TGF-b concentration. The levels of TGF-b in the sera from
chronic HCV patients were significantly elevated when compared to healthy controls (450 vs. 64 mg/ml, p,0.05).
doi:10.1371/journal.pone.0070744.g003
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fibroblasts with pre-miR200c and stimulated them with TGF-b for
24 hrs. The cells were treated with Src inhibitor-1 (10 mM) or
controls during stimulation with TGF-b. Analysis of the FGF levels
in the cSrc inhibitor treated cells showed no significant increase
(4.26 0.3 vs 0.860.3, p.0.05) in the FGF levels in the miR200c
transfected fibroblasts when compared to controls (figure 6). These
results also support the conclusion that miR200c through FAP-1
modulates the cSrc signaling cascade which can promote
development of fibrosis.
miR200c and its gene targets that promote development
of fibrosis is modulated in chronic HCV
Analysis of miRNA and mRNA arrays suggested that HCV
infection can modulate the growth factor signaling through the
modulation of miR200c. In order to validate the microarray data,
we analyzed the levels of miR 200c, FAP1 and cSrc that modulate
the growth factor signaling cascades by quantitative RT-PCR. The
levels of miR200c in the liver biopsies obtained from 10 HCV
infected livers with inflammation but no fibrosis, 10 HCV infected
livers with grade III/IV fibrosis and 10 liver biopsies from patients
with non-alcoholic steatohepatitis (NASH) were analyzed by
quantitative RT-PCR using TaqManH MicroRNA Assay. RT-
PCR analysis of the miRNA levels in the chronic HCV infected
liver (figure 7a) demonstrated a 3.3 60.9 fold increase in the levels
of miR 200c in the chronic HCV infected liver whereas the levels
in the HCV infected livers with inflammation but no fibrosis (1.1
fold) and NASH (0.9 fold) showed no significant increase in the
levels of miR200c when compared to the normal livers (figure 7a).
The levels of FAP-1 (figure 7b) the immediate target of miR200c
was down regulated by 2.6 fold in the chronic HCV infected liver
with fibrosis but was not affected in HCV livers with no fibrosis
(1.3 fold) or in NASH (1.0 fold). However, the levels of cSrc
(figure 7c) were significantly elevated in chronic HCV (3.2 6 0.4)
and NASH (2.4 6 0.7) but not in HCV infected liver with no
fibrosis (1.7 6 1.1).These results demonstrate that HCV infection
leads to a significant modulation of the miRNA profile that
promotes development of fibrosis following chronic HCV infec-
tion. Similarly, analysis of the FAP-1 levels demonstrated a 2.1 fold
reduction in the HCV infected livers with fibrosis, 1.6 fold
reductions in the NASH but showed no significant reduction in
HCV infected liver with inflammation but no fibrosis when
compared to control normal livers. These observations that the
increase in miR200c and decrease in the FAP-1 levels in the HCV
infected liver but not in the NASH livers suggest that chronic
HCV infection through the modulation of miR200c promotes the
development of fibrosis.
Discussion
Chronic HCV infection is one of the major indications for
hepatitis, cirrhosis and hepatocellular carcinoma worldwide.
Figure 4. Increased miR200c decreases FAP-1 expression. Human liver fibroblasts were transfected with pre-miR200c miRNA or scrambled
miRNA (200 nM) using Lipofectamine RNAiMax and stimulated with TGF-b (50 ng/mL). RNA was isolated using trizol reagent and expression levels of
miR200c and FAP-1 were measured using pre-developed Taqman miRNA and mRNA assays respectively. The small RNA U6b (miRNA) and GAPDH
(mRNA) was used as an endogenous control and relative levels was calculated by the DDCt method. Bars represent the mean expression observed in
3 different experiments performed with 3 different fibroblasts. In order to further define the role of miR200c, we cotransfected fibroblasts with pre-
miR200c and mirVanaH miRNA inhibitor for miR200c and analyzed for the expression levels of miR200c and FAP-1. Cotransfection with mirVanaH
miRNA inhibitor (50 nM) resulted in restoration of the levels of miR200c and FAP-1 to the levels observed in the untreated fibroblasts. a) Relative
expression levels of miR200c; b: Relative expression levels of FAP-1 at the mRNA level; c: Relative expression levels of FAP-1 at the protein level and d:
Representative western blot analysis of FAP-1. Lanes 1) Fibroblasts; 2) Fibroblast + TGF-b; 3) Fibroblast + TGF-b+pre-miR-miR200c; 4) Fibroblast + TGF-
b+ scrambled pre-miR; 5) Fibroblast + TGF-b+ pre-miR –miR200c+ mirVanaH miRNA inhibitor control; and 6) Fibroblast + TGF-b+ pre-miR –miR200c+
mirVanaH miRNA inhibitor miR200c.
doi:10.1371/journal.pone.0070744.g004
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Chronic HCV infection results in increased production of
profibrotic cytokines and growth factors that result in fibrosis
and cirrhosis of the liver leading to loss of liver functions. One
potential mechanism by which HCV can evade the immune
responses and induces fibrosis is through the modulation of
miRNA levels that play a critical role in the gene expression. In
this study, we demonstrate that chronic HCV infection results in
the modulation of 45 miRNAs that alter growth factor signaling
pathway, cell cycle regulation, epithelial mesenchymal transition
and chemokines and cell adhesion that could promote fibrosis and
immune evasion leading to loss of liver function. We also
demonstrate that HCV infection, by increasing the levels of
miR-200c, down modulates the expression of FAP1 or PTPN13, a
regulator of c-Src activation. Decreased expression of FAP-1
results in increased cSrc activation following growth factor
signaling leading to increased production of pro-fibrogenic growth
factors and components of extracellular matrix that promotes the
development of fibrosis.
Analysis of the miRNA profile showed a .2 fold increase in the
expression of 22 miRNAs and .2 reduction in the expression of
23 miRNAs. Functional grouping of the miRNAs based on the in
silico target prediction and network building identified activation
of phospholipase C pathway, cellular response to endogenous
stimuli (growth factors and cytokine), and cellular proliferation as
the major biological processes impacted by the modulated
miRNAs. Similar to our studies, a distinct miRNA profile has
been associated with HCV infection [24]. By comparing liver
biopsies from HCV+ and HCV- LTx the authors demonstrated a
significant increase in the expression of miR16 and down
regulation of miR122 [24]. Similarly, an increase in the expression
of miR-122, miR-100, miR-10a, miR198 and miR-145 has also
been reported in HCV induced HCC tissues when compared to
adjacent non-tumor tissue [25]. Shackle et al has also reported that
in HCV-associated cirrhosis the genes up regulated were
Figure 5. miR200c through modulation of growth factor signaling through cSrc activation promotes fibrosis. Human liver fibroblasts
transfected with miR200c or scrambled miRNA were stimulated with TGF-b and analyzed for the expression of: a) cSrc at the message level by
quantitative RT-PCR and b) relative expression levels of cSrc and FGF at protein level, c) representative western blot analysis of cSrc, and d)
representative western blot analysis of FGF. miR200c overexpression results in a significant increase in expression of cSrc at the message level (2.6
fold) and cSrc and FGF at the protein level (3.1 and 4.2 fold respectively). Bars represent the mean relative expression levels from 3 different
experiments performed with 3 different fibroblasts.
doi:10.1371/journal.pone.0070744.g005
Figure 6. Src Inhibition reverses the action of miR200c. Human
liver fibroblasts transfected with miR200c were stimulated with TGF-b in
the presence of Src inhibitor (10 mM) or PBS control. a) Expression levels
of FGF were analyzed at the protein level by western blot analysis. Bars
represent the mean relative expression observed in 3 different set of
experiments performed with 3 different fibroblasts. b) representative
western blot analysis of FGF levels. Treatment with Src inhibitor
decreased the levels of FGF expression in the miR200c transfected cells
to the levels observed in the untransfected fibroblasts.
doi:10.1371/journal.pone.0070744.g006
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predominantly associated with a Th1 immune response, fibrosis,
cellular proliferation, and apoptosis [26]. A study using a whole
genome array has also reported that genes of the immune system,
extracellular matrix turnover, anti-apoptotic pathway, interferon
pathway and virus host interactions are differentially expressed in
the liver biopsies from chronic HCV when compared to normal
livers [27]. However, the mechanism by which HCV modulates
the differential gene expression has not been explored. In silico
analysis of the miRNA by complementary pairing analysis suggest
that each miRNA could potentially target multiple mRNAs and
impact their expression profile. Partek analysis identified 289
potential interactions that can modulate several biological
processes including metabolic processes, cell proliferation and
response to stimulus. In order to further validate these studies, we
analyzed the levels of TGF-b expression in sera of 20 chronic
HCV patients and compared them to normal subjects. Significant
increases (.8 fold) in the levels of TGF-b in chronic HCV infected
patients when compared to normal controls (figure 3). Since
increased TGF-b levels can increase the production of extracel-
lular matrix proteins and their receptors and inhibit the synthesis
of matrix-degradative proteolytic enzymes we postulate that HCV
infection through the modulation of TGF-b signaling can promote
immune evasion, viral persistence as well as induction of fibrosis
leading to end stage liver disease.
Fibrosis is the critical event in liver cirrhosis leading to loss of
liver functions. We defined that chronic HCV infection results in
the modulation of miRNA 10b and 200c which can regulate the
expression of transcription factors, Homeobox D10 and ZFHX1B
[28]. It has been reported that the interactions of yEF1/ZEB1 and
the miRNA-200 family members miR-141 and miR-200c are part
of a transcriptional feed forward loop that stabilizes epithelial
mesenchymal transition (EMT) and promotes cancer invasion
[29]. Microdissected metaplastic breast carcinoma has been shown
to have a specific loss of miR-200 which correlates with increased
expression of vimentin and decreased E-cadherin in the mesen-
chymal component [30,31]. Therefore, significant modulation of
miRNA 141, 200 and 10c seen in our analysis can result in the
modulation of the expression of transcription factors that promote
the induction of EMT.
Binding of TGF-b to its cognate receptor on the target cells
results in recruitment of Smad proteins that translocates to the
nucleus and with coactivators results in the increased profibrotic
and anti-apoptotic genes that contribute to the development of
fibrosis [32,33] Src kinases are important mediators of pro-fibrotic
signaling pathways [34,35] and can modulate the activity of TGF-
b signaling by phosphorylating and activating TGF-b type II
receptor and the downstream target c-Abl [36]. A specific
inhibitor of Src kinase (SU6656) can effectively abrogate fibrosis
in an experimental model of fibrosis [37]. FAP1 or PTPN13, a
nonreceptor type protein tyrosine phosphatase with the highest
molecular weight, 270 kDa, contains multiple interactive domains
has been shown to directly interact with Src and modulates its
downstream effects [38]. It has been shown that miR200c can
directly modulate the expression of FAP-1 [39]. In our study,
miRNA expression profiling of the chronic HCV livers demon-
strated a 2.9 fold increase (Table 2) in the expression of miR200c
which was then validated by quantitative RT-PCR in a set of 10
chronic HCV samples (figure 7a). We also identified that the
miRNA 200c target FAP1 is significantly down regulated in
chronic HCV (figure 7b). A significant (3-6 fold) increase in the
expression of TGF-b , FGF, VEGF, and PDGF in chronic HCV
liver was also noted along with significant increases (2–8 fold) in
the expression of ECM proteins collagen, fibronectin and vimentin
(Table S1). Using in vitro methods, we demonstrated that
transfection of human fibroblasts with miR200c results in a 2.1
fold decrease in expression of FAP-1 (figure 4b) with a
corresponding 2.2 fold increase in the levels of activated cSrc
(figure 4C) leading to a 3.4 fold increase in expression of FGF
(figure 5) and 4.2 fold increase in expression of FGF (figure 5).
Blocking of Src signaling through an inhibitor (Src inhibitor-1)
following transfection with miR200c of liver fibroblasts did not
result in the increased expression of FGF or Col-V (figure 6).
Based on these, we conclude that the increased levels of miR200c
in the chronic HCV infected liver results in the decreased
expression of FAP-1, the negative regulator of Src kinase leading
to dysregulated TGF-b signaling that promotes development of
fibrosis. A putative pathway through which modulated miRNAs in
chronic HCV infected liver that promotes fibrosis is presented in
figure 2.
In conclusion, using miRNA expression profiling and whole
genome array analysis we demonstrate that chronic HCV
infection results in the modulation of several miRNAs. We also
present evidence that HCV infection increases the levels of a
specific miRNA, miR200c which regulates the expression of FAP-
1, a negative regulator and impacts the growth factor signaling
pathway by modulating the Src kinase signaling cascade plays an
important role in development of fibrosis.
Figure 7. Modulation of growth factor signaling cascade in chronic HCV infection. Liver biopsies were obtained from 10 HCV infected
patients with inflammation but no fibrosis, 10 HCV infected patients with grade III/IV fibrosis and 10 patients with NASH. Expression levels of: a)
mIR200c; b) FAP-1 and c) cSrc were analyzed by quantitative RT-PCR using pre-developed Taqman miRNA assays. The small RNA U6b was used as an
endogenous control and relative miRNA quantity was calculated by the DDCt method. The horizontal line represents the average and standard
deviation of fold expression levels in the groups.
doi:10.1371/journal.pone.0070744.g007
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Supporting Information
Table S1 Transcription profile of the chronic HCV
liver. Total RNA was isolated from the liver biopsies and mRNA
expression analysis was done using the Illumina HumanHT-12 v3
Expression BeadChips array that contains (48000) probe sets.
Gene expression levels in the samples were normalized based on
the 16s ribosomal RNAs and housekeeping gene expression.
PARTEK analysis software was used to analyze the differential
expression profile of the genes. Changes in gene expression level of
2-fold or more in the HCV samples compared with the normal
controls with p value ,0.05 (based on ANOVA analysis) were
considered to be significant. Chronic HCV patients had greater
than two fold increases in the expression of 785 genes and greater
than 2 fold reduction in the expression of 533 genes.
(PDF)
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